Syqe Medical

Company Overview

Snapshot

Founded in March 2011 by Perry Davidson, Syqe Medical operates with 51–200 employees. The company has raised $72.65 million across three funding rounds from seven investors. In November 2023, Syqe Medical's SyqeAir Inhaler obtained ARTG approval in Australia, marking a significant milestone for metered-dose cannabis treatment.

Business overview

Syqe Medical is a MedTech company specializing in a programmable drug-delivery inhalation platform for medical cannabis. Its core product, the SyqeAir Inhaler, enables precise and metered dosing of medical cannabis by inhalation, adhering to standard-of-care principles for effective and safe treatment. The platform aims to provide personalized doses for pain reduction and improved sleep quality with minimal adverse effects, enhancing patients' quality of life. The company operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Medical Devices, serving patients in markets such as Israel and Australia.

Strategic signal

In July 2025, Syqe Medical announced layoffs of 50 employees, approximately one-third of its workforce, primarily in the development department. This strategic adjustment aims to reallocate resources towards securing FDA approval for its cannabis inhaler, SyqeAir. This move signals a critical pivot for the company, prioritizing regulatory clearance in the US market, which is also a contingency for its potential acquisition by Philip Morris.

Company Intelligence Q&A

What is the current status of Syqe Medical's acquisition by Philip Morris?

In July 2025, it was reported that Syqe Medical is in the process of being acquired by Philip Morris for approximately $650 million, contingent on FDA approval for its SyqeAir inhaler. Philip Morris has already invested $120 million to support the approval process.

What recent operational changes has Syqe Medical implemented?

In July 2025, Syqe Medical laid off 50 employees, representing one-third of its workforce, mainly from the development department. This restructuring aims to focus resources on securing US regulatory clearance for its product.

Has Syqe Medical received any recent product approvals?

In November 2023, Syqe Medical's SyqeAir Inhaler obtained ARTG approval in Australia, making it the first and only metered-dose cannabis inhaler to receive such approval in the country.

What partnerships has Syqe Medical established for its products?

In November 2023, Syqe Medical signed a strategic agreement with the Israeli Ministry of Defense to provide its inhaler to veterans suffering from chronic pain and PTSD. Previously, in June 2023, the National Insurance Institute entered an exclusive agreement with Syqe to fully finance medical cannabis treatment for victims of hostilities.

What was the company's most recent funding round?

In December 2018, Syqe Medical completed a B Round of funding. Investors in this round included Shavit Capital Fund and OurCrowd.